C86.61
BillablePrimary cutaneous CD30-positive T-cell proliferations, in remission
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C86.61 an HCC code?
Yes. C86.61 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C86.61
For C86.61 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C86.61 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C86.61 is the ICD-10-CM diagnosis code for primary cutaneous cd30-positive t-cell proliferations, in remission. A type of skin cancer involving abnormal T-cells that are CD30-positive and have responded well to treatment with no signs of disease remaining. C86.61 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C86.61 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C86.61 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
This code specifically indicates remission status; use C86.60 if remission status is unknown or not achieved. Because C86.61 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C86.61 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This code specifically indicates remission status; use C86.60 if remission status is unknown or not achieved
- •Document the specific type of cutaneous lymphoma and current treatment response in the medical record
Clinical Significance
Primary cutaneous CD30-positive T-cell proliferations in remission indicates the skin lymphoma has responded to treatment with resolution of active lesions. The generally favorable prognosis of primary cutaneous CD30-positive disease means remission is achievable in many patients. However, some entities in this spectrum (particularly lymphomatoid papulosis) have a characteristically relapsing-remitting course requiring ongoing dermatologic surveillance.
Documentation Requirements
- ✓Provider must explicitly document remission with evidence of resolved skin lesions on clinical examination.
- ✓The original diagnosis confirming CD30-positive T-cell proliferation must be in the record.
- ✓Dermatologic surveillance plan and any concern for transformation to a more aggressive lymphoma should be documented.